TICKERNERD
Menu
PHVSPHVSHealthcare · Biotechnology

PHVS Stock Forecast: Pharvaris NV Price Predictions for 2026-2027

Last close, 21 Aug 2026
$36
−0.33% on the day

The 13 Wall Street analysts covering Pharvaris NV hold a median 12-month price target of $47 — +28.3% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 42 of 100 as at 22 Aug 2026 — in the lower half.

Market cap
$2.5B
Ticker Nerd rank
42 / 100
Median analyst target
$47
Analysts covering
13
Total return, dividends reinvested
1W
+3.2%
1M
+5.3%
YTD
+30.7%
1Y
+55.3%
From 52W high
−0.5%
From 52W low
+73.0%
$21
$36
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

PHVS stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Pharvaris NV on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 22 Aug 2026
42 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Momentum
92
Volatility
89
Value
62
Growth
49
Accruals
45
Revisions
34
Quality
34
Size
33
Issuance
29

Momentum (92): The shares have been drifting up relative to others.

Issuance (29): The company has been issuing shares or taking on financing, diluting existing holders.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

PHVS stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on PHVS, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$20$30$40$50$60$70$80Oct 25Jan 26Apr 26Jul 26PHVSHigh $76Median $47Low $38

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

What Wall Street says13 analysts
12 Buy1 Hold0 Sell
Low $38Median $47High $76

The green dot is the last close — the median target sits +28.3% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 4 moved their price target up and 0 moved it down.

DateFirmActionRatingTarget
13 Aug 2026CitizensMaintainsMarket Outperform$74 → $75
13 Aug 2026GuggenheimMaintainsBuy$39 → $40
13 Aug 2026RBC CapitalMaintainsOutperform$51 → $52
15 July 2026Wells FargoInitiatesOverweight$55
15 July 2026Wells FargoInitiatesOverweight—
25 June 2026Morgan StanleyMaintainsOverweight$41 → $46
25 June 2026Morgan StanleyMaintainsOverweight—
13 May 2026CitizensMaintainsMarket Outperform—
9 Apr 2026Wolfe ResearchInitiatesOutperform—
7 Apr 2026WedbushMaintainsOutperform—
6 Apr 2026RBC CapitalMaintainsOutperform—
9 Mar 2026RBC CapitalInitiatesOutperform—
3 Mar 2026HC Wainwright & Co.ReiteratesBuy—
4 Dec 2025B of A SecuritiesMaintainsNeutral—
4 Dec 2025GuggenheimMaintainsBuy—
4 Dec 2025Morgan StanleyMaintainsOverweight—
4 Dec 2025OppenheimerMaintainsOutperform—
3 Dec 2025HC Wainwright & Co.ReiteratesBuy—
14 Nov 2025Morgan StanleyMaintainsOverweight—
13 Nov 2025HC Wainwright & Co.ReiteratesBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. PHVS appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Estimates

PHVS analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
0
Analysts cutting
2
Fundamentals

Pharvaris NV (PHVS) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−12.2×

Cheaper than 94% of US stocks

Price / sales
—
Price / book
7.3×

Cheaper than 15% of US stocks

EV / EBITDA
−12.2×

Cheaper than 85% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
0.0%

Higher than 32% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−70.5%

Higher than 17% of US stocks

Return on assets
−42.3%

Higher than 10% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

PHVS vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
PHVSPharvaris NV$2.5B
42
RAREUltragenyx Pharmaceutical, Inc.$2.5B
49
PGENPrecigen, Inc.$2.5B
82
TRVITrevi Therapeutics, Inc.$2.5B
54
NKTRNektar Therapeutics$2.5B
52
NUVBNuvation Bio, Inc.$2.4B
63
ATAIAtai Beckley, Inc.$2.7B
28

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Pharvaris NV — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest PHVS news & analysis

Pharvaris Reports Second Quarter 2026 Financial Results and Provides Business Update

GlobeNewsWire · 12 Aug 2026neutral

Pharvaris announced financial results for the second quarter ending June 30, 2026, and provided a business update. The company is a late-stage biopharmaceutical firm developing oral bradykinin B2 receptor antagonists for bradykinin-mediated angioedema, including hereditary angioedema and acquired angioedema due to C1 inhibitor deficiency.

Why it matters — PHVS watchers would follow this quarterly financial and business update for insight into the company's progress and financial standing as it advances its late-stage angioedema programs.

Assessment of AAE-C1INH Disease Burden and Validation of Clinical Trial Endpoints Published in Frontiers in Immunology

GlobeNewsWire · 6 Aug 2026positive

Pharvaris announced that results from a qualitative study assessing the experiences of people with AAE-C1INH and validating patient-reported outcome measures were published in Frontiers in Immunology. The findings informed the design and endpoint selection for the ongoing Phase 3 CREAATE study investigating deucrictibant for prophylaxis and on-demand treatment of AAE-C1INH attacks.

Why it matters — The peer-reviewed publication supports the validity of the endpoints being used in Pharvaris's ongoing Phase 3 CREAATE study for deucrictibant in AAE-C1INH.

Pharvaris: One Molecule Could Reshape Both Sides Of HAE Treatment

Seeking Alpha · 4 Aug 2026positive

Pharvaris' NDA for deucrictibant immediate-release (IR) was accepted by the FDA with a PDUFA date of April 23, 2027, following strong Phase 3 RAPIDe-3 results. The company is also developing an extended-release (XR) form, with CHAPTER-3 Phase 3 data expected in Q3 2026, which is described as a pivotal catalyst for its HAE franchise.

Why it matters — PHVS watchers would care because regulatory progress on the IR form and upcoming XR data indicate whether Pharvaris can become an end-to-end hereditary angioedema treatment platform.

Wall Street Analysts Think Pharvaris (PHVS) Could Surge 43.03%: Read This Before Placing a Bet

Zacks Investment Research · 31 July 2026positive

A Zacks Investment Research article notes that the consensus price target for Pharvaris (PHVS) implies a 43% upside potential, though it cautions that such targets are often unreliable. The article also observes that an upward trend in earnings estimate revisions could indicate near-term upside for the stock.

Why it matters — PHVS watchers would care because the article signals that analysts are revising earnings estimates upward, which could influence near-term perception of the stock.

FAQ

Frequently asked questions about PHVS stock

What is the PHVS stock price forecast for 2026-2027?

The 13 Wall Street analysts covering Pharvaris NV have a median 12-month price target of $47, with estimates ranging from $38 to $76. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is PHVS stock a buy right now?

Of the 13 analysts covering Pharvaris NV, 12 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Pharvaris NV 42 out of 100 across roughly 4,600 US stocks as at 22 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank PHVS?

As at 22 Aug 2026, Pharvaris NV ranks 42 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Momentum (92 of 100).

Will PHVS stock go up?

No one can know that. What the data says: the median 12-month target from 13 analysts implies +28.3% from the last close, and Ticker Nerd's factor model ranks Pharvaris NV 42 out of 100 as at 22 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the PHVS stock forecast for 2030?

No analyst covering Pharvaris NV publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for PHVS are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $38 to $76 over the next 12 months.

How has PHVS stock performed over the past year?

Pharvaris NV returned +55.3% over the 12 months to 21 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Pharvaris NV do?

Pharvaris N.V. is a biopharmaceutical company that specializes in discovering, developing, and commercializing innovative therapies to treat hereditary angioedema (HAE) and other bradykinin B2 receptor-mediated diseases.

What is the latest news on PHVS?

The most recent item we track (GlobeNewsWire, 12 Aug 2026): "Pharvaris Reports Second Quarter 2026 Financial Results and Provides Business Update". Pharvaris announced financial results for the second quarter ending June 30, 2026, and provided a business update. The company is a late-stage biopharmaceutical firm developing oral bradykinin B2 receptor antagonists for bradykinin-mediated angioedema, including hereditary angioedema and acquired angioedema due to C1 inhibitor deficiency.

Company

About Pharvaris NV.

Pharvaris N.V. is a biopharmaceutical company that specializes in discovering, developing, and commercializing innovative therapies to treat hereditary angioedema (HAE) and other bradykinin B2 receptor-mediated diseases. With its headquarters in Leiden, the Netherlands, Pharvaris is prominently focused on addressing unmet medical needs within the biopharmaceutical industry. The company's key product candidates are designed to provide an oral alternative to injectable therapies for HAE, promising convenience and broader accessibility for patients. Through its research and development efforts, Pharvaris contributes significantly to the healthcare sector by advancing treatment options for rare genetic conditions. Its innovative approach to treatment aims to enhance patient quality of life and improve therapeutic outcomes. As a player in the biotechnology domain, Pharvaris is integral to ongoing developments in genetic and rare disease treatments, reflecting the increasing significance and demand for targeted medicinal solutions in modern healthcare.

CEO Mr. Berndt Axel Edvard Modig CPA, M.B.A. · 148 employees · Switzerland · https://pharvaris.com